CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Light Delivery Device (LDD)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04005586
NCT04005586N/ACompleted
CompareCT.gov

A Prospective Controlled Multi-Center Clinical Study to Evaluate The Safety and Effectiveness of Performing 0.50 Diopter Astigmatism Correction on the Commercially Available RxSight Light Adjustable Lens (LAL)

RxSight, Inc.·interventional·Posted Jul 2, 2019·Updated Jun 11, 2021

In Brief

A clinical study evaluating Light Delivery Device (LDD) for Aphakia and Cataract. Completed, enrolled 25 participants across 2 sites.

Detailed Summary

The primary objective of this study is to evaluate the safety and effectiveness of performing 0.50 D cylinder correction on the RxSight Light Adjustable Lens (LAL) in patients who have undergone implantation with the FDA approved, commercially available LAL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAphakia, Cataract
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedJul 2, 2019
Enrollment StartJul 1, 2019
Primary CompletionMar 1, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 7 years ago

Interventions

Light Delivery Device (LDD)device

Study eye will undergo Light delivery Device treatments